Indications and uses
Indication and usage 1. Recap the bottle after use. 2. Avoid exposure to a high or low temperature of direct sunlight
Belucie Luxury Essential foundation BB
- Manufacturer
- KIMJEONGMOON ALOE CO., LTD. | COSMAX INC.
- Effective date
- 2012-11-29
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:33:50
Label at a glance#
ProductBelucie Luxury Essential foundation BB ANTI WRINKLE SPF20 PA PLUS PLUS
Active ingredientTitanium Dioxide
Label structure8 sections
Dosage and administration
Dosage and administration After suitable amount of pumping, tap lightly and spread carefully depending on your skin texture.
Label contents#
Full prescribing information#
ACTIVE INGREDIENT
Active Ingredient: Titanium Dioxide (CI 77891) 9.29496%
INACTIVE INGREDIENT
Inactive Ingredients : Water, Cyclopentasiloxane, Glycerin, Cyclohexasiloxane, Triethylhexanoin, Butylene Glycol Dicaprylate/Dicaprate, Cetyl PEG/PPG-10/1 Dimethicone, Sodium Chloride, Disteardimonium Hectorite, Sorbitan Olivate, Sorbitan Isostearate, Simmondsia Chinensis (Jojoba) Seed Oil, Iron Oxides (CI 77492), Talc, Trimethylsiloxysilicate, Dimethicone, Dimethicone/Vinyl Dimethicone Crosspolymer, Iron Oxides (CI 77491), Iron Oxides (CI 77499), Phenoxyethanol, Methylparaben ,Fragrance(Parfum), Triethoxycaprylylsilane, Aluminum Hydroxide, Glyceryl Behenate, Polyglyceryl-6 Octastearate, Stearic Acid, Propylparaben, Disodium EDTA, Adenosine, Chlorphenesin, Butylene Glycol, Morus Alba Bark Extract, Acorus Gramineus Root/Stem Extract, Polyperfluoromethylisopropyl Ether, Aloe Barbadensis Leaf Extract, Chrysanthellum Indicum Extract, Lonicera Japonica (Honeysuckle) Flower Extract, Nelumbo Nucifera Flower Extract, Carthamus Tinctorius (Safflower) Flower Extract, Laminaria Saccharina Extract, Camellia Sinensis Leaf Extract, Angelica Keiskei Leaf/Stem Extract, Rubus Suavissimus (Raspberry) Leaf Extract, Bacillus/Soybean Ferment Extract, Glycine Soja (Soybean) Oil, Lecithin, Butylparaben, Ethylparaben, Alcohol Denat., Isobutylparaben, rh-Oligopeptide-1
PURPOSE
Purpose: UVA/UVB Protection
WARNINGS
Warnings
1. In case of having following symptoms after using this, you’re advised to stop using it immediately. If you keep using it, the symptoms will get worse and need to consult a dematologists.
2. In case of having problems such as red spots, swelling, itching and irritation during usage
3. In case the above symptoms emerge due to direct exposure to sunlight
4. Please do not apply the skin to areas affected by eczema and dermatitis
KEEP OUT OF REACH OF CHILDREN
KEEP OUT OF REACH OF CHILDREN
INDICATIONS AND USAGE
Indication and usage
1. Recap the bottle after use.
2. Avoid exposure to a high or low temperature of direct sunlight
DOSAGE AND ADMINISTRATION
Dosage and administration
After suitable amount of pumping, tap lightly and spread carefully depending on your skin texture.
PACKAGE LABEL. PRINCIPAL DISPLAY PANEL
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 8801201050359 | GTIN-13: 8801201050359 EAN-13: 8801201050359 GTIN storage (14 digits): 08801201050359 | belucie luxury essential foundation bb carton.jpg |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 50410-030-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0f10-f424-e053-dadaa90a57ce | 13fa6da6-1a69-4c82-b3a5-e736215363c7 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50410-030-01 | Belucie Luxury Essential foundation BBANTI WRINKLE SPF20 PA PLUS PLUS | 35 mL in 1 CARTON | CREAM | 35 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50410-030 | BELUCIE LUXURY ESSENTIAL FOUNDATION BB ANTI WRINKLE SPF20 PA PLUS PLUS (TITANIUM DIOXIDE) CREAM [KIMJEONGMOON ALOE CO., LTD.] | 1 | Legacy NDC, 1 package rows | 20121129_13fa6da6-1a69-4c82-b3a5-e736215363c7.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Titanium Dioxide | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| Butylene Glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Triethylhexanoin | INACTIVE INGREDIENT | 7K3W1BIU6K | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Belucie Luxury Essential foundation BB ANTI WRINKLE SPF20 PA PLUS PLUS
- Titanium Dioxide
- Water
- Glycerin
- Triethylhexanoin
- Butylene Glycol
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 50410-030 | 50410-030-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Titanium Dioxide | 15FIX9V2JP | ACTIM |
| Water | 059QF0KO0R | IACT |
| Glycerin | PDC6A3C0OX | IACT |
| Triethylhexanoin | 7K3W1BIU6K | IACT |
| Butylene Glycol | 3XUS85K0RA | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| Butylene Glycol | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| Butylene Glycol | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TOPICAL | 1400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f0420d22-97a6-4ad2-8e95-e9fa1ec0d74b | 13fa6da6-1a69-4c82-b3a5-e736215363c7 | 2012-11-29 | Warnings | f0420d22-97a6-4ad2-8e95-e9fa1ec0d74b 13fa6da6-1a69-4c82-b3a5-e736215363c7 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.